Stem Cell Therapy Successfully Treats Heart Attack in Animals; Patients Enrolled for Phase 1 Clinical Trial幹細胞療法成功治療心髒病發作在動物;病人參加第1期臨床試驗
Results of a study show that stem cell therapy can be used effectively to treat heart attacks in pigs.一項研究的結果表明，幹細胞療法可有效地用於治療心髒病發作在豬體內的。 In just two months, stem cells harvested from another pig’s bone marrow and injected into the animal’s damaged heart restored heart function and repaired damaged heart muscle by 50 percent to 75 percent.在短短的兩個月內，幹細胞的收穫從另一個豬的骨髓，並注入到動物的受損心臟恢復心臟功能和修復損壞的心臟肌肉的50 ％至75 ％ 。
This confirms the results from AIIMS -這證實了的結果，從aiims - AIIMS pioneers stem cell injection for reviving heart muscles aiims的先驅幹細胞注射恢復心臟肌肉
To quote from AIIMS report:引述aiims報告：
As part of a path breaking study.作為一個組成部分，打破路徑研究。 conducted from February 2003 to January 2005, 35 cardiac patients have been given stem cell treatment and have been monitored at 6, 12 and 18 month intervals.進行了從2003年2月至2005年1月， 35個心臟手術患者已獲得幹細胞治療，並已監測6 ，第12和18個月的間隔。
After six months, 56% of the affected (read dead muscles) area injected with these cells had shown improvement.在6個月後， 56 ％的受影響（閱讀死亡的肌肉）轄區內注入這些細胞已顯示出改善的地方。 After eighteen months, this went up to 64%.後18個月，這上升到64 ％ 。
Final results of a study conducted at Johns Hopkins show that stem cell therapy can be used effectively to treat heart attacks, or myocardial infarction, in pigs.最終結果進行的一項研究，在約翰霍普金斯表明，幹細胞療法可有效地用於治療心髒病發作，或心肌梗死，在豬體內的。 In just two months, stem cells harvested from another pig’s bone marrow and injected into the animal’s damaged heart restored heart function and repaired damaged heart muscle by 50 percent to 75 percent.在短短的兩個月內，幹細胞的收穫從另一個豬的骨髓，並注入到動物的受損心臟恢復心臟功能和修復損壞的心臟肌肉的50 ％至75 ％ 。
The Hopkins findings, first presented last fall at the 2004 Scientific Sessions of the American Heart Association, are to be published in the latest issue of the Proceedings of the National Academy of Sciences online the week of July 25.該霍普金斯大學的調查結果，首先介紹了去年秋天在2004年科學會議的美國心臟協會，是將刊登在最新一期的Proceedings of the National Academy of Sciences的在線週7月25日。
Two patients have already been enrolled at Hopkins in a Phase I clinical trial, which is designed to test the safety of injecting adult stem cells at varying doses in patients who have recently suffered a heart attack.兩名病人已就讀於霍普金斯在I期臨床試驗，這是旨在測試的安全注射成人幹細胞在不同劑量的病人在誰最近遭受了心髒病發作。 In total, 48 patients will participate in this study, which is happening at several sites across the country.在共計48例，將參與這項研究，這是發生在幾個網站該國各地。 Results are not expected until mid-2006.結果，我們並不預期到2006年中期。
“Ultimately, the goal is to develop a widely applicable treatment to repair and reverse the damage done to heart muscle that has been infarcted, or destroyed, after losing its blood supply,” says cardiologist Joshua Hare, MD, professor of medicine at The Johns Hopkins University School of Medicine and its Heart Institute, and senior author of the study and lead trial investigator. “最終，目標是建立一個廣泛適用的治療修復和扭轉的損害做了心臟肌肉已梗死，或者摧毀後，失去其血液供應，說： ”心臟約書亞野兔，醫學博士，醫學教授約翰霍普金斯大學醫學院和其心臟研究所，和高級研究報告的作者，並導致審判的調查。
However the claim made by cardiologist Joshua Hare is wrong - “There is reason for optimism about these findings, possibly leading to a first-ever cure for heart attack in humans”.不過，索賠所作出的心臟約書亞野兔是錯誤的 -“有樂觀的理由對這些調查結果，可能導致了第一次治療心髒病發作，在人類” 。
This is not the first time.這是不是第一次了。 AIIMS is the pioneer in this field aiims是先驅，在這一領域 . 。
The researchers are using a special kind of stem cell in an early stage of development, called adult mesenchymal stem cells, to avoid potential problems with immunosuppression, in which every human’s immune system might attack stem cells from sources other than itself.研究人員正在使用一種特殊的幹細胞在早期發展階段，所謂的成人間質幹細胞，以避免潛在的問題與免疫抑制，在這種每個人的免疫系統可能的攻擊幹細胞以外的其他來源本身。 Bone marrow adult stem cells do not have the same potential to develop into different organ tissues, as do embryonic stem cells, whose use is more controversial.骨髓成人幹細胞不具有相同的潛力發展成不同的器官組織一樣，胚胎幹細胞，其使用的是較具爭議性。
